Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Urologix March Stock Price Gain Propelled By BPH Systems, Disposables

This article was originally published in The Gray Sheet

Executive Summary

Increased market penetration and improved reimbursement rates for Urologix, Inc.'s Targis Cooled ThermoTherapy system for treatment of benign prostatic hyperplasia (BPH) translated into a nearly 30% stock price gain in March. The issue advanced $4.17 to close at $18.17 for the month

You may also be interested in...

Medtronic Fishes For Urology Growth, Lands TUNA BPH Device With VidaMed

Medtronic's $326 mil. acquisition of VidaMed is expected to close in January 2002, just as Medicare reimbursement for the firm's transurethral needle ablation (TUNA) system for benign prostatic hyperplasia (BPH) increases from $2,455 per procedure to $3,043

Urologix' Targis

Production of the microwave-based system for benign prostatic hyperplasia begins at Plexus Corp. under a two-year manufacturing agreement announced Oct. 24. Initial deliveries from Plexus are slated for December. Quality system deficiencies have hampered production at Colorado MEDtech under a previous arrangement (1"The Gray Sheet" Aug. 13, 2001, p. 13). Minneapolis-based Urologix continues to develop redundant, in-house manufacturing facilities for the device, approved by FDA in 1997, and expects completion by mid-2002

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts